Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Glioblastoma 12Central Nervous System Neoplasms 11Brain Neoplasms 9Astrocytoma 8Glioma 6Oligodendroglioma 4Gliosarcoma 3Neoplasms 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1Multiple Myeloma 1Cognition Disorders 1

Interventions

Cytarabine 89Daunorubicin 45Azacitidine 43Idarubicin 27venetoclax 26fludarabine 26Etoposide 25Cyclophosphamide 25Mitoxantrone 22Decitabine 19Busulfan 19Methotrexate 16Gemtuzumab 14Granulocyte Colony-Stimulating Factor 12Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10gilteritinib 9Filgrastim 9fludarabine phosphate 8Tacrolimus 8Mycophenolic Acid 8Cyclosporine 8Tretinoin 7Radiotherapy 7Drug Therapy 7Observation 6Homoharringtonine 6Antilymphocyte Serum 6quizartinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myeloid, Acute × Lomustine × Clear all
NCT00590837 2014-04-02

LAM-SA 2007

University Hospital, Bordeaux

Phase 3 Completed
459 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00480064 2007-05-30

Lomustine and Intermediate Dose Cytarabine in Older Patients With AML

French Innovative Leukemia Organisation

Phase 3 Completed
360 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡